生物制剂治疗炎症性肠病失应答的研究现状及进展  

Current research status and progress in biologic therapy for inflammatory bowel disease non-response

作　　者：木出布都木 欧阳淼[1] Muchu Bu-du-mu;Ouyang Miao(Department of Gastroenterology,Xiangya Hospital,Central South University,Changsha,Hunan 410008,China)

机构地区：[1]中南大学湘雅医院消化内科,湖南长沙410008

出　　处：《中国现代医学杂志》2024年第21期52-57,共6页China Journal of Modern Medicine

基　　金：国家自然科学基金(No:82370566)。

摘　　要：过去的二十年中,随着炎症性肠病(IBD)研究的不断深入,生物制剂对中度、重度IBD的治疗愈发重要,但生物制剂的失应答使得IBD的治疗依然面临巨大挑战,目前尚无对该类患者治疗的临床建议或指南。该文就各生物制剂治疗IBD的失应答情况做一综述,并深入了解目前生物制剂失应答的研究现状,为IBD的临床治疗提供一定参考。In the past two decades,with the deepening of the research on inflammatory bowel disease,biologics have become more and more important for the treatment of moderate to severe inflammatory bowel disease,but the failure of biologics to respond to the treatment of IBD still faces great challenges,and there are no clinical recommendations or guidelines for the treatment of such patients.This article reviews the response of various biological agents in the treatment of inflammatory bowel disease and understands the current research progress of biological agent response,so as to provide some reference for the clinical treatment of IBD.

关 键 词：炎症性肠病 生物制剂 原发性失应答 继发性反应丧失 

分 类 号：R574[医药卫生—消化系统]